Single CRISPR infusion reduces hereditary angioedema attacks by 87% in phase 3 trial
A single intravenous dose of Intellia Therapeutics’ in vivo CRISPR-Cas9 therapy lonvoguran ziclumeran (lonvo-z) reduced monthly hereditary angioedema attacks by 87% compared with placebo in a phase 3…
Read the full articleYou might also wanna read
Intellia Therapeutics Aktie: Lonvo-z startet FDA-Verfahren
Intellia Therapeutics erlebt turbulente Tage an der Börse. Während die Forschungserfolge der CRISPR-Spezialisten eigentlich Hoffnung machen,
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) ve
FDA·2mo agoLynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-s
The Latest Data from Lenadogene Nolparvovec Gene Therapy Trials for Leber Hereditary Optic Neuropathy - Part 4
In the final episode of this four-part series, Dr. Justin Abbatemarco and Dr. Nancy Newman discuss the abstract she presented at the AAN Ann
Zoetis Aktie: Lenivia in Kanada und EU zugelassen
Das US-amerikanische Unternehmen Zoetis treibt seine Wachstumsstrategie im Bereich der Tiergesundheit mit einer zweigleisigen Strategie vora
Nava Therapeutics Launches with $89M to Advance Extrahepatic LNP Delivery for In Vivo CAR-T and Kidney Gene Editing
July 16, 2026 — Nava Therapeutics has launched with $89 million in funding to advance a lipid nanoparticle platform designed to deliver RNA
Comments
Sign in to join the conversation.
No comments yet. Be the first.